Log In
BCIQ
Print this Print this
 

glembatumumab vedotin (CDX-011) (formerly CR011-vcMMAE)

Also known as: formerly CR011

  Manage Alerts
Collapse Summary General Information
Company Celldex Therapeutics Inc.
DescriptionAntibody-drug conjugate (ADC) composed of a humanized IgG2 mAb against glycoprotein NMB (GPNMB) and monomethyl auristatin E (MMAE)
Molecular Target Glycoprotein NMB (GPNMB) ; Tubulin
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$93.5M

$93.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/05/2009

$93.5M

$93.5M

0

Get a free BioCentury trial today